Testing HS-20093 for advanced prostate and other solid cancers
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or spread cancer that hasn't responded to available treatments
- You have at least one tumor that can be seen on scans
- You are able to care for yourself (fully active or limited only in strenuous activity)
- You haven't had a drug that targets B7-H3 (a specific protein on some cancer cells) before
- You can provide a sample of your tumor tissue (old or new)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Hear when a new Metastasis Castration Resistant Prostate Cancer(mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.